BioRestorative presents promising data for autologous stem cell therapy for chronic lumbar disc disease

From GlobeNewswire: 2025-06-13 07:45:00

The ISSCR 2025 Annual Meeting showcased a >50% improvement in pain and function for a significant number of chronic lumbar disc disease (cLDD) subjects. The number of evaluated subjects has doubled since the last update, with promising data shared by BioRestorative Therapies, Inc. at the event. Preliminary results from the ongoing Phase 2 clinical trial of BRTX-100, an autologous stem cell therapy, met the FDA’s requirements for function and pain reduction. Over 74% of subjects showed >50% improvement in function, and over 72% reported >50% reduction in pain. The data indicate a positive trend in efficacy and safety for the therapy, which could offer a non-surgical solution for chronic lower back pain.



Read more at GlobeNewswire: BioRestorative Reports Compelling Preliminary Data for